Sigridur Jonsdottir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sigridur Jonsdottir has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Sigurbjörg Torsteinsdóttir
Institute for Experimental Pathology, Biomedical Center, University of Iceland, Keldur, Keldnavegur 3, 112, Reykjavik, Iceland
2 shared publications - A. Douglas Wilson
University of Bristol, Clinical Research and Imaging Centre, Bristol, United Kingdom
1 shared publication - Anja Ziegler
Department of Clinical Research and Veterinary Public Health Vetsuisse Faculty‐University of Bern Länggass‐strasse 124 Bern 3012 Switzerland
1 shared publication - Antonia Fettelschoss-Gabriel
Department of Dermatology University Hospital Zurich Schlieren Switzerland
1 shared publication - Arna Runarsdottir
ORF Genetics Ltd., Vikurhvarfi 7, 203, Kopavogur, Iceland
1 shared publication Eliane Marti
Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Berne, Länggass-Strasse 124, 3012, Berne, Switzerland
1 shared publication
Latest Publications
- Open Access
- 18 November 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (6) , 579-e156
Immunopathogenesis and immunotherapy of Culicoides hypersensitivity in horses: an update
Culicoides hypersensitivity (CH) is a strongly pruritic dermatitis of horses, characterised histologically by mixed perivascular to diffuse cellular infiltrates of mononuclear cells and eosinophils, and caused by helper T cell (Th)2, immunoglobulin (Ig)E‐mediated reactions to antigens present in the saliva of biting Culicoides midges. As treatment of CH is still not satisfactory, a better knowledge of the pathogenesis of CH is needed for the development of new therapeutic modalities. Accordingly, availability of pure Culicoides allergens instead of crude whole body extracts is essential for the improvement of in vitro diagnosis of CH and development of a more effective allergen immunotherapy (AIT). Beside the Th2 cytokines interleukin (IL)‐4 and IL‐13, recent studies have shown the involvement of thymic stromal lymphopoietin, IL‐5 and IL‐31 in the pathogenesis of CH. The importance of IL‐5 and IL‐31 has been confirmed through targeting these cytokines by active immunisation of CH patients, resulting in a significant decrease of CH lesion scores. Thirty Culicoides salivary allergens have been described over the last 10 years and produced as pure recombinant (r‐) proteins. Use of a protein microarray has allowed the identification of the most relevant Culicoides r‐allergens for CH in central and northern Europe. An immunisation protocol has been developed for preventive AIT against CH. Small amounts of r‐Culicoides allergens injected into the submandibular lymph nodes with Alum/MPLA as adjuvants seem to induce a suitable immune response for both preventive and therapeutic AIT. The next years will reveal whether these recent advancements will translate into an improved diagnosis, treatment and prevention of CH.
- 18 November 2021
- Published by Wiley in Veterinary Dermatology
- Vol. 32 (6) , 579-e156
Open AccessImmunopathogenesis and immunotherapy of Culicoides hypersensitivity in horses: an update
Culicoides hypersensitivity (CH) is a strongly pruritic dermatitis of horses, characterised histologically by mixed perivascular to diffuse cellular infiltrates of mononuclear cells and eosinophils, and caused by helper T cell (Th)2, immunoglobulin (Ig)E‐mediated reactions to antigens present in the saliva of biting Culicoides midges. As treatment of CH is still not satisfactory, a better knowledge of the pathogenesis of CH is needed for the development of new therapeutic modalities. Accordingly, availability of pure Culicoides allergens instead of crude whole body extracts is essential for the improvement of in vitro diagnosis of CH and development of a more effective allergen immunotherapy (AIT). Beside the Th2 cytokines interleukin (IL)‐4 and IL‐13, recent studies have shown the involvement of thymic stromal lymphopoietin, IL‐5 and IL‐31 in the pathogenesis of CH. The importance of IL‐5 and IL‐31 has been confirmed through targeting these cytokines by active immunisation of CH patients, resulting in a significant decrease of CH lesion scores. Thirty Culicoides salivary allergens have been described over the last 10 years and produced as pure recombinant (r‐) proteins. Use of a protein microarray has allowed the identification of the most relevant Culicoides r‐allergens for CH in central and northern Europe. An immunisation protocol has been developed for preventive AIT against CH. Small amounts of r‐Culicoides allergens injected into the submandibular lymph nodes with Alum/MPLA as adjuvants seem to induce a suitable immune response for both preventive and therapeutic AIT. The next years will reveal whether these recent advancements will translate into an improved diagnosis, treatment and prevention of CH.
- Open Access
- 1 August 2021
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 238, 110289
Comparison of recombinant Culicoides allergens produced in different expression systems for IgE serology of insect bite hypersensitivity in horses of different origins
- 1 August 2021
- Published by Elsevier in Veterinary Immunology and Immunopathology
- Vol. 238, 110289
Open AccessComparison of recombinant Culicoides allergens produced in different expression systems for IgE serology of insect bite hypersensitivity in horses of different origins